Plasma levels of adipokines in systemic lupus erythematosus patients

Cytokine

Volumn 86, Issue , 2016, Pages 15-20

  Zhang, Tian Ping ^a,b   Li, Hong Miao ^a,b   Leng, Rui Xue ^a,b   Li, Xiang Pei ^c   Li, Xiao Mei ^c   Pan, Hai Feng ^a,b   Ye, Dong Qing ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Provincial Laboratory of Population Health and Major Disease Screening and Diagnosis   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Adipokines; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ADIPOCYTOKINE; CATHEPSIN L; CATHEPSIN S; CHEMERIN; COMPLEMENT FACTOR D; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OMENTIN 1; UNCLASSIFIED DRUG; CATHEPSIN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADIPOCYTOKINE BLOOD LEVEL; ADULT; ARTICLE; CATHEPSIN L BLOOD LEVEL; CATHEPSIN S BLOOD LEVEL; CHEMERIN BLOOD LEVEL; CLINICAL EVALUATION; COMPLEMENT FACTOR D BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN BLOOD LEVEL; OMENTIN 1 BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; MIDDLE AGED; YOUNG ADULT;

ADIPOKINES; ADULT; CATHEPSINS; COMPLEMENT FACTOR D; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GPI-LINKED PROTEINS; HUMANS; LECTINS; LIPOCALIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; YOUNG ADULT;

EID: 84978387014     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.07.008     Document Type: Article

References (50)

1. [1] Gill, J.M., et al. Diagnosis of systemic lupus erythematosus. Am. Fam. Physician 68:11 (2003), 2179–2186.
2. [2] Sherer, Y., Zinger, H., Shoenfeld, Y., Atherosclerosis in systemic lupus erythematosus. Autoimmunity 43:1 (2010), 98–102.
3. [3] Chung, C.P., et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis. 66:2 (2007), 208–214.
4. [4] Katz, P., et al. Impact of obesity on functioning among women with systemic lupus erythematosus. Arthritis Care Res. 63:10 (2011), 1357–1364.
5. [5] Lago, F., et al. Adipokines as emerging mediators of immune response and inflammation. Nat. Clin. Pract. Rheumatol. 3:12 (2007), 716–724.
6. [6] Ikeoka, D., Mader, J.K., Pieber, T.R., Adipose tissue, inflammation and cardiovascular disease. Rev. Assoc. Med. Bras. 56:1 (2010), 116–121.
7. [7] Hutcheson, J., Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:2 (2015), 272–279.
8. [8] Afroze, D., et al. Serum leptin levels, leptin receptor gene (LEPR) polymorphism, and the risk of systemic lupus erythematosus in Kashmiri population. Immunol. Invest. 44:2 (2015), 113–125.
9. [9] De Sanctis, J.B., et al. Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 42:4 (2009), 272–274.
10. [10] Wislowska, M., et al. Serum leptin in systemic lupus erythematosus. Rheumatol. Int. 28:5 (2008), 467–473.
11. [11] Rovin, B.H., et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int. 68:4 (2005), 1825–1833.
12. [12] McMahon, M., et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann. Rheum. Dis. 70:9 (2011), 1619–1624.
13. [13] Li, H.M., et al. Plasma/serum leptin levels in patients with systemic lupus erythematosus: a meta-analysis. Arch. Med. Res. 46:7 (2015), 551–556.
14. [14] Huang, Q., et al. Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Clin. Rheumatol. 34:10 (2015), 1713–1720.
15. [15] Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 40(9), 1997, 1725.
16. [16] Pan, H.F., et al. Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients. Rheumatol. Int. 33:9 (2013), 2337–2342.
17. [17] Gladman, D.D., Ibanez, D., Urowitz, M.B., Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29:2 (2002), 288–291.
18. [18] Zhao, X.F., et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol. Biol. Rep. 37:1 (2010), 81–85.
19. [19] Zhang, H., et al. Effect of Roux-en-Y gastric bypass on remission of T2D: medium-term follow-up in Chinese patients with different BMI obesity class. Obes. Surg., 2016.
20. [20] Alcelik, A., et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press. Res. 35:6 (2012), 511–516.
21. [21] Schaffler, A., et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta 1732:1–3 (2005), 96–102.
22. [22] de Souza Batista, C.M., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56:6 (2007), 1655–1661.
23. [23] Kuperman, D.A., et al. Dissecting asthma using focused transgenic modeling and functional genomics. J. Allergy Clin. Immunol. 116:2 (2005), 305–311.
24. [24] Xu, L., et al. Synovial fluid omentin-1 levels are inversely correlated with radiographic severity of knee osteoarthritis. J. Investig. Med. 60:3 (2012), 583–586.
25. [25] Hietaharju, A., et al. Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study. Eur. J. Neurol. 17:2 (2010), 332–334.
26. [26] Swingler, T.E., et al. Degradome expression profiling in human articular cartilage. Arthritis Res. Ther., 11(3), 2009, R96.
27. [27] Sturfelt, G., et al. Serum level of complement factor D in systemic lupus erythematosus-an indicator of glomerular filtration rate. Acta Med. Scand., 216, 1984.
28. [28] Sturfelt, G., Sjoholm, A.G., Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int. Arch. Allergy Appl. Immunol. 75 (1984), 75–83.
29. [29] Triebel, S., et al. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett., 314(3), 1992.
30. [30] Shen, F., et al. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281:34 (2006), 24138–24148.
31. [31] Shen, F., et al. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-alpha-induced genes in bone cells. J. Leukoc. Biol. 77:3 (2005), 388–399.
32. [32] Gupta, K., et al. Neutrophil gelatinase–associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum. 56:10 (2007), 3326–3335.
33. [33] Katano, M., et al. Implication of granulocyte-macrophage colony-stimulating factor induced neutrophil gelatinase-associated lipocalin in pathogenesis of rheumatoid arthritis revealed by proteome analysis. Arthritis Res. Ther., 11(1), 2009, R3.
34. [34] Pawar, R.D., et al. Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalin. Clin. Immunol. 154:1 (2014), 49–65.
35. [35] Sharifipour, F., et al. Association of urinary lipocalin-2 with lupus nephritis. Iran J. Basic Med. Sci. 16:9 (2013), 1011–1015.
36. [36] Brunner, H.I., et al. Urinary neutrophil gelatinase–associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 54:8 (2006), 2577–2584.
37. [37] Pitashny, M., et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 56:6 (2007), 1894–1903.
38. [38] Rubinstein, T., Pitashny, M., Putterman, C., The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. Autoimmun. Rev. 7:3 (2008), 229–234.
39. [39] Pfau, D., et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 33:1 (2010), 171–173.
40. [40] Vermi, W., et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J. Exp. Med. 201:4 (2005), 509–515.
41. [41] De Palma, G., et al. The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int. 79:11 (2011), 1228–1235.
42. [42] Conus, S., Simon, H.-U., Cathepsins and their involvement in immune responses. Swiss Med. Wkly.(140), 2010.
43. [43] Reddy, V.Y., Zhang, Q.-Y., Weiss, S.J., Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocytederived macrophages. Proc. Natl. Acad. Sci., 92, 1995.
44. [44] Rl, T., et al. Cathepsin S inhibitors as novel immunomodulators. Curr. Opin. Investig. Drugs, 6(5), 2005.
45. [45] Chapman, H.A., Endosomal proteases in antigen presentation. Curr. Opin. Immunol. 18:1 (2006), 78–84.
46. [46] Rupanagudi, K.V., et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann. Rheum. Dis. 74:2 (2015), 452–463.
47. [47] Graham, K.L., et al. Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J. Immunol. 183:10 (2009), 6717–6723.
48. [48] Xu, J., et al. Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice. Mediators Inflamm. 2013 (2013), 1–11.
49. [49] Yamashita, T., et al. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. Exp. Dermatol., 2015.
50. [50] Nakagawa, T., Cathepsin L: critical role in ii degradation and CD4 T cell selection in the thymus. Science 280:5362 (1998), 450–453.